Quick 5 min look at their results:
- Targeted adults (Neuren was 5-15 years old)
- Smaller sample size (25 patients vs Neuren's 82)
- Much smaller dose (5mg daily vs up to 200mg/kg for Neuren's trial)
- More statistically significant results in CGI(P values of 0.014 vs Neuren's 0.029)
- Similar statistically significant results in RSBQ (0.048 vs Neuren's 0.042)
Looks good for Anavex.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.88 |
Change
-0.140(1.00%) |
Mkt cap ! $1.727B | |||
| Open | High | Low | Value | Volume |
| $13.90 | $14.21 | $13.64 | $4.590M | 329.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 600 | $13.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.96 | 2894 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |